Fatal hepatotoxicity due to sevoflurane use in a paediatric patient after aortic repair: reality or fiction? A case of pharmacovigilance.

Eur J Hosp Pharm

Cardiac Surgery Unit, Cardiac, Thoracic, Vascular and Public Health Science Department, Padova University Hospital, Padova, Italy.

Published: January 2023

AI Article Synopsis

  • Hepatotoxicity from volatile anesthetics is rare but clinically important due to their common use, unpredictable onset, and potential severity.
  • Halothane is the anesthetic most associated with liver dysfunction, particularly upon re-exposure, while cases involving sevoflurane are very uncommon.
  • A 1-year-old girl developed severe acute hepatitis and died after surgery with sevoflurane, leading to the case's serious classification in national and European pharmacovigilance systems to enhance patient safety and inform medical literature.

Article Abstract

Hepatotoxicity secondary to exposure of volatile anaesthetics is an exceptional finding, but its clinical interest depends on their frequent use, unpredictable appearance and potential severity. Halothane is the volatile anaesthetic most frequently involved in the development of liver dysfunction, especially after re-exposure. Sevoflurane has rarely been related to this life-threatening complication. We present the case of a 1-year-old girl who had undergone previous surgery for closure of a patent ductus arteriosus, and who developed severe acute hepatitis and died after undergoing surgical repair of an aortic isthmus narrowing by means of general anaesthesia with sevoflurane. Other possible causes of liver failure were excluded. This adverse event was classified as serious and was included in the national and European pharmacovigilance network, with the aim of preventing dangerous effects on patient health in clinical practice, by contributing to the enrichment of the literature.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811565PMC
http://dx.doi.org/10.1136/ejhpharm-2020-002610DOI Listing

Publication Analysis

Top Keywords

fatal hepatotoxicity
4
hepatotoxicity sevoflurane
4
sevoflurane paediatric
4
paediatric patient
4
patient aortic
4
aortic repair
4
repair reality
4
reality fiction?
4
fiction? case
4
case pharmacovigilance
4

Similar Publications

Mushroom Poisoning and Acute Liver Injury: A Case-Based Review.

Cureus

December 2024

Acute Medicine, Princess Royal University Hospital, King's College Hospital NHS Foundation Trust, Orpington, GBR.

Mushrooms have always found their way into our dining plates due to their exotic looks and edibility. It is also one of the food items that can lead to fatal hepatotoxicity if the wrong species is picked up. Mushroom poisoning is frequently seen in forest adventure seekers and presents with variable time frames, mainly with acute gastrointestinal symptoms.

View Article and Find Full Text PDF

Hepatotoxicity is an under-recognized and potentially fatal side effect of high-dose methotrexate (HDMTX) chemotherapy, and this risk is compounded in children with metabolic dysfunction-associated steatotic liver disease and/or metabolic-associated steatohepatitis. We present the case of a 12-year-old obese, Hispanic male with elevated hepatic transaminases of unknown etiology at initiation of high-risk B-cell acute lymphoblastic leukemia chemotherapy. He developed acute kidney injury within 24 hours of receiving intravenous HDMTX which progressed to acute hepatic failure.

View Article and Find Full Text PDF

Systemic Toxicity of Recombinant Adeno-Associated Virus Gene Therapy Vectors.

Toxicol Pathol

December 2024

Sanofi, Cambridge, Massachusetts, USA.

Recombinant adeno-associated virus (rAAV) vectors have emerged as a promising tool for gene therapy. However, the systemic administration of rAAV vectors is not without risks, particularly for dose levels >1 × 10 viral genome per kilogram of body weight (vg/kg). rAAV-associated toxicities can variably manifest either acutely or in a delayed manner.

View Article and Find Full Text PDF

Temozolomide (TMZ)-levetiracetam (LEV) combination therapy in glioblastoma management is gradually becoming a mainstay treatment given its superior effect compared with TMZ monotherapy. While there have been previous cases of hepatotoxicity, there are no prior reports of vanishing bile duct syndrome (VBDS) associated with TMZ-LEV combination use. This case report details a male in his 50s who had recently completed TMZ and LEV for right frontal lobe glioblastoma.

View Article and Find Full Text PDF

Background: After the risk of drug-induced liver injury was detected during tolvaptan clinical development for the treatment of autosomal dominant polycystic kidney disease (ADPKD), a post-marketing pharmacovigilance study was required for European Union regulatory approval.

Methods: This is an interim analysis from a prospective, observational study enrolling patients prescribed tolvaptan for ADPKD in routine clinical practice. Data were obtained through physician records collected during regular care.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!